BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report published on Friday. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of NASDAQ BIOL opened at $0.01 on Friday. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94. The company has a market capitalization of $300,663.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. The business has a 50-day moving average of $0.01 and a 200-day moving average of $0.01.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.